{"publication_id":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","content_hash":"sha256:4a8bd67aac2606251055150a5a3056a3e15ffbef1117c4e7026b1db44620d9f9","nodes":[{"id":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","type":"publication","title":"metformin exercise training adaptation"},{"id":"claim_1","type":"claim","text":"**Alpha (1 sentence):** The same drug class anchor (\"antidiabetes agent + exercise\") splits by compound — dapagliflozin lets adaptation signal travel, while metformin both impairs adaptation and independently protects muscle from damage — so a single \"protection\" tag cannot be treated as a benefit on the exercised-muscle endpoint."},{"id":"claim_2","type":"claim","text":"**Receipt 1:** Konopka et al., *Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training* (J Clin Endocrinol Metab, 2019; doi:10.1210/jc.2018-01741) — 12-week RCT, n=30 sedentary overweight/obese adults; dapagliflozin (≤10 mg/d) + supervised endurance training preserved favorable body-mass, body-composition, and VO₂peak adaptations."},{"id":"claim_3","type":"claim","text":"**Receipt 2:** *Metformin Protects Rat Skeletal Muscle from Physical Exercise-Induced Injury* (Biomedicines, 2023; doi:10.3390/biomedicines11092334) — healthy rats, 8 weeks metformin + moderate daily exercise; reduced serum muscle-injury markers (ALT/AST/LDH/CK-MB) and blunted histological damage versus untreated exercising rats."},{"id":"claim_4","type":"claim","text":"**Why surprising:** Two studies launched from overlapping anchors (\"antidiabetes drug + endurance exercise\") diverge on the exercised muscle itself."},{"id":"claim_5","type":"claim","text":"Receipt 1 shows the SGLT2i does not block the training response; Receipt 2 shows metformin reduces exercise-induced muscle damage markers — a \"protective\" signal that sits next to, not inside, the adaptation literature reporting metformin *attenuates* training gains (as flagged in Receipt 1's framing)."},{"id":"claim_6","type":"claim","text":"**Caveats / Falsifiers:** (a) Receipt 2 is rodent, healthy, 8 weeks — not a human performance or adaptation trial; (b) reduced CK-MB/LDH is a damage *marker* signal, not an established functional or clinical endpoint and does not by itself demonstrate improved muscle performance; (c) species, dose, and training-intensity mismatches to Receipt 1 preclude direct ranking; (d) Receipt 1's own intro cites metformin attenuating adaptation, meaning the \"Met = protective\" framing in Receipt 2 is silent on that adjacent adverse finding."},{"id":"claim_7","type":"claim","text":"**Selection basis:** Chosen because the pair holds the anchor constant (antidiabetes drug + endurance exercise) while the compound changes, isolating drug identity as the variable behind opposite-sign results on related but non-identical endpoints."},{"id":"claim_8","type":"claim","text":"**Next test / gap:** A head-to-head rodent protocol measuring, in the same animals, both endurance-training adaptation (VO₂max, mitochondrial markers) and exercise-induced muscle damage (CK-MB, histology) under metformin vs."},{"id":"claim_9","type":"claim","text":"vehicle — to test whether metformin's damage-marker reduction coexists with attenuated adaptation in the same cohort, or whether the protection and attenuation signals are dissociable."},{"id":"source_1","type":"source","study":"Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training.","year":2019,"doi":"10.1210/jc.2018-01741","url":"https://doi.org/10.1210/jc.2018-01741","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The combination of two beneficial antidiabetes interventions, regular exercise and pharmaceuticals, is intuitively appealing. However, metformin, the most commonly prescribed diabetes medication, attenuates the favorable physiological adaptations to exercise; in turn, exercise may impede the action of metformin. We sought to determine the influence of an alternative diabetes treatment, sodium glucose cotransporter 2 (SGLT2) inhibition, on the response to endurance exercise training. In a randomized, double-blind, repeated measures parallel design, 30 sedentary overweight and obese men and women were assigned to 12 weeks of supervised endurance exercise training, with daily ingestion of either a placebo or SGLT2 inhibitor (dapagliflozin: ≤10 mg/day). Endurance exercise training favorably modified body mass, body composition (dual-energy x-ray absorptiometry), peak oxygen uptake (graded exercise with indirect calorimetry), responses to standardized submaximal exercise (indirect calorimetry, heart rate, and blood lactate), and skeletal muscle (vastus lateralis) citrate synthase activity (main effects of exercise training, all P 0.05). However, after endurance exercise training, fastin"},{"id":"source_2","type":"source","study":"Metformin Protects Rat Skeletal Muscle from Physical Exercise-Induced Injury","year":2023,"doi":"10.3390/biomedicines11092334","url":"https://doi.org/10.3390/biomedicines11092334","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Metformin (Met) is a drug commonly prescribed in type 2 diabetes mellitus. Its efficacy is due to the suppression of hepatic gluconeogenesis, enhancement of peripheral glucose uptake and lower glucose absorption by the intestine. Recent studies have reported Met efficacy in other clinical applications, such as age-related diseases. Despite the wide clinical use of Met, its mechanism of action on muscle and its effect on muscle performance are unclear. We investigated the effects of Met combined with training on physical performance (PP) in healthy rats receiving Met for 8 weeks while undergoing daily moderate exercise. We evaluated the following: PP through graded endurance exercise test performed before the beginning of the training protocol and 48 h before the end of the training period; blood ALT, AST, LDH and CK-MB levels in order to address muscle damage; and several blood and muscle myokines and the expression of factors believed to be involved in muscle adaptation to exercise. Our data demonstrate that Met does not improve the positive effects of exercise on performance, although it protects myocytes from exercise-induced damage. Moreover, given that Met positively affects e"}],"edges":[{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_1","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_2","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_3","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_4","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_5","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_6","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_7","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_8","type":"contains_claim"},{"from":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","to":"claim_9","type":"contains_claim"}],"screening":{"identified":2,"screened":2,"excluded":0,"included":2,"included_or_retained":2,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"2 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}